← All studies

2024 · Hirano — Successful treatment of myalgic encephalomyelitis/chronic fatigue syndrome using hydrogen gas: four case reports.

Original title: Successful treatment of myalgic encephalomyelitis/chronic fatigue syndrome using hydrogen gas: four case reports.

Super-Abstract

Four patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) — one of medicine's most intractable and poorly understood conditions — are reported to have improved with hydrogen gas inhalation therapy. Full abstract text was not available for this entry; findings are based on title and metadata only. (Medical Gas Research, 2024.)

Classified as a Pilot / Observational study using Inhalation. See Methodology for how we grade evidence.

Commentary

ME/CFS is characterised by post-exertional malaise, profound fatigue, cognitive impairment, and autonomic dysfunction. It has no established effective pharmacological treatment, making any positive report of interest. Hydrogen gas inhalation is biologically plausible in ME/CFS given the condition's proposed links to mitochondrial dysfunction, neuroinflammation, and oxidative stress — all targets of H₂'s documented effects. However, ME/CFS research has a long history of promising case reports that did not translate to controlled trials. The series of four cases is slightly more informative than a single case, but without the full abstract or text, no specific details about patient selection, H₂ dosing protocol, outcome measures, or follow-up duration can be assessed.

Our assessment

No abstract was available for this entry — assessment is based on title and metadata only. ME/CFS is a clinically important indication with no approved treatments, making this series worth noting. H₂'s proposed mechanism (mitochondrial support, neuroinflammation reduction, ROS scavenging) aligns with current ME/CFS pathophysiology hypotheses. However, four case reports without controls cannot establish efficacy. Limitations: n=4; no control arm; full details unavailable; ME/CFS diagnosis criteria and outcome measures unknown; placebo response in ME/CFS can be substantial.

Study design

Source & links

Screenshot of the PubMed page

Screenshot — PubMed 37929512

This page mirrors the published abstract (© the authors / publisher) for reference and citation. The canonical source is the PubMed record linked above. This is not medical advice.